Barry Sexton serves as the Senior Finance Director for Global External Manufacturing at Bristol Myers Squibb, where he plays a pivotal role in driving financial strategy and operational excellence across a vast network of contract manufacturers. With over $600 million in annual spend and a...
Barry Sexton serves as the Senior Finance Director for Global External Manufacturing at Bristol Myers Squibb, where he plays a pivotal role in driving financial strategy and operational excellence across a vast network of contract manufacturers. With over $600 million in annual spend and a diverse portfolio of 110 external partners, Barry's expertise in financial modeling and capital projects is instrumental in optimizing resource allocation and enhancing profitability. His strategic financial leadership extends to providing critical business insights and acting as a change agent for strategic initiatives, ensuring alignment with the company's overarching goals.
In his current role, Barry collaborates closely with the Senior Vice-President of Global External Manufacturing, leveraging his extensive experience in the pharmaceutical industry to navigate complex financial landscapes. His background as a General Manager of a distribution and virtual manufacturing center has equipped him with a unique blend of commercial acumen and supply chain knowledge, allowing him to effectively manage internal controls and corporate tax implications while fostering a culture of continuous improvement.
Barry's proficiency in SAP and auditing further enhances his ability to streamline processes and implement robust financial frameworks that support the company's growth objectives. As a seasoned professional, he is committed to driving change management initiatives that not only improve operational efficiency but also contribute to Bristol Myers Squibb's mission of delivering innovative therapies to patients worldwide. Through his strategic insights and collaborative approach, Barry Sexton continues to be a key asset in navigating the evolving landscape of the pharmaceutical industry.
